2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109072
    Riamilovir
    		Inhibitor
    Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of SARS-CoV-2.
    Riamilovir
  • HY-170819
    VK13
    		Inhibitor
    VK13 (Compound 6) is a potent inhibitor of human cathepsin L (hCatL) with a Ki value of 0.55 nM and SARS-CoV-2 3CLpro (3CL-PR) with a Ki value of 2.6 nM. VK13 exhibits anti-CoV-2 activity with an EC50 of 1.25 μM.
    VK13
  • HY-W028142R
    Quipazine (Standard)
    		Inhibitor
    Quipazine is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research.
    Quipazine (Standard)
  • HY-174439
    Nsp12-IN-2
    		Inhibitor
    Nsp12-IN-2 (Compound 8), the triphosphate metabolite of 4'-thiouridine (HY-W113081), is a SARS-CoV-2 Nsp12 inhibitor. Nsp12-IN-2 inhibits the RNA-dependent RNA polymerase (RdRp) activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp8 complex, terminates RNA synthesis and also blocks the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 is promising for research of infections caused by SARS-CoV-2, other coronaviruses, and other RNA viruses.
    Nsp12-IN-2
  • HY-B1624
    Debrisoquin
    		Inhibitor
    Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC50 of 22μM. Debrisoquin can be used for antiviral research.
    Debrisoquin
  • HY-157439
    SARS-CoV-2-IN-72
    		Inhibitor
    SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-COV-2 papain-like protease domain that can trigger the degradation of NSP3.
    SARS-CoV-2-IN-72
  • HY-173134
    SARS-CoV-2 RdRp-IN-1
    		Inhibitor
    SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities.
    SARS-CoV-2 RdRp-IN-1
  • HY-170599
    H117
    		Inhibitor 99.27%
    H117 is a PROTAC target protein ligand that can be used to synthesize PROTAC HP211206 (HY-170598). H117 has competitive binding and inhibition ability on SARS-CoV-2 main protease (Mpro) with an IC50 of 151.3 nM.
    H117
  • HY-B1028R
    Pantethine (Standard)
    		Inhibitor
    Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration.
    Pantethine (Standard)
  • HY-175325
    SARS-CoV-2-IN-116
    		Inhibitor
    SARS-CoV-2-IN-116 (Compound (S,S)-4) is a highly selective angiotensin-converting enzyme 2 (ACE2) inhibitor (pIC50=7.61). SARS-CoV-2-IN-116 blocks the interaction between SARS-CoV-2 spike protein and ACE2. SARS-CoV-2-IN-116 is promising for research of COVID-19.
    SARS-CoV-2-IN-116
  • HY-169047
    PAMAM dendrimer G1.5 carboxylate sodium
    		Inhibitor
    PAMAM dendrimer G1.5 carboxylate (PAMAM G1.5 carboxylate) sodium is a polyanionic dendrimers comprising the terminal groups sodium carboxylate. PAMAM dendrimer G1.5 carboxylate shows antiviral activity with the MERS‐CoV plaque inhibition assay, with the inhibition rate of 40.5%.
    PAMAM dendrimer G1.5 carboxylate sodium
  • HY-168473
    13-TP
    		Inhibitor
    13-TP is an inhibitor of SARS-CoV-2. 13-TP effectively inhibits the SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp82) catalyzed in vitro RNA synthesis. 13-TP completely inhibits the RdRp polymerization activity. 13-TP blocks the full extension of some of the primer RNA.
    13-TP
  • HY-14904R
    Umifenovir (Standard)
    		Inhibitor
    Umifenovir (Standard) is the analytical standard of Umifenovir. This product is intended for research and analytical applications. Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro. Umifenovir shows anti-inflammatory activity.
    Umifenovir (Standard)
  • HY-12530S1
    Velpatasvir-d3
    		Inhibitor
    Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
    Velpatasvir-d<sub>3</sub>
  • HY-159933
    SARS-CoV-2-IN-105
    		Inhibitor
    SARS-CoV-2-IN-105 (Compound 4a) is a SARS-CoV-2 inhibitor with the EC50 of 0.69 μM.
    SARS-CoV-2-IN-105
  • HY-163067
    SARS-CoV-2-IN-71
    		Inhibitor
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CLpro and TMPRSS2.
    SARS-CoV-2-IN-71
  • HY-B0402AR
    Amantadine hydrochloride (Standard)
    		Inhibitor
    Amantadine (hydrochloride) (Standard) is the analytical standard of Amantadine (hydrochloride). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) hydrochloride is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine hydrochloride inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine hydrochloride also has anti-orthopoxvirus and anticancer activity. Amantadine hydrochloride can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research.
    Amantadine hydrochloride (Standard)
  • HY-169501
    WIN 62577
    		Inhibitor
    WIN 62577 is a species-selective tachykinin NK1 receptor antagonist. WIN 62577 is also an allosteric enhancer with micromolar potency at M3 receptors. WIN 62577 exhibits potent antiviral activity against SARS-CoV-2.
    WIN 62577
  • HY-14768S
    Favipiravir-13C15N
    		Inhibitor
    Favipiravir-13C15N (T-705-13C15N) is 13C and 15N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
    Favipiravir-<sup>13</sup>C<sup>15</sup>N
  • HY-17437AR
    Mefloquine hydrochloride (Standard)
    		Inhibitor
    Mefloquine (hydrochloride) (Standard) is the analytical standard of Mefloquine (hydrochloride). This product is intended for research and analytical applications. Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research.
    Mefloquine hydrochloride (Standard)
Cat. No. Product Name / Synonyms Species Source